Dewpoint Therapeutics vs Tempus

Side-by-side comparison of AI visibility scores, market position, and capabilities

Tempus leads in AI visibility (74 vs 36)
Dewpoint Therapeutics logo

Dewpoint Therapeutics

EmergingLife Sciences & BioTech

Biomolecular Condensate Drug Discovery Platform

Dewpoint Therapeutics pioneers drug discovery targeting biomolecular condensates — liquid-like protein assemblies implicated in cancer, neurodegeneration, and metabolic disease; raised over $160M;

AI VisibilityBeta
Overall Score
D36
Category Rank
#104 of 198
AI Consensus
75%
Trend
stable
Per Platform
ChatGPT
32
Perplexity
39
Gemini
32

About

Dewpoint Therapeutics is a Boston-based biotechnology company founded in 2018 by Richard Young, Tony Hyman, and Clifford Brangwynne — three of the world's leading researchers in the science of biomolecular condensates. Condensates are dynamic, liquid-like assemblies of proteins and nucleic acids that form within cells through a process called phase separation. Dewpoint's thesis is that many diseases — including cancer, neurodegeneration, and metabolic disorders — involve the dysregulation of these condensates, and that drugs targeting condensate behavior represent a new class of therapies beyond conventional target-based drug discovery.

Full profile
Tempus logo

Tempus

LeaderLife Sciences & BioTech

AI-Enabled Precision Medicine

Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.

AI VisibilityBeta
Overall Score
B74
Category Rank
#11 of 198
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
71
Perplexity
68
Gemini
80

About

Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.

Full profile

AI Visibility Head-to-Head

36
Overall Score
74
#104
Category Rank
#11
75
AI Consensus
68
stable
Trend
stable
32
ChatGPT
71
39
Perplexity
68
32
Gemini
80
41
Claude
77
34
Grok
69

Key Details

Category
Biomolecular Condensate Drug Discovery Platform
AI-Enabled Precision Medicine
Tier
Emerging
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.